Forschungsprojekte
Ergebnisse pro Seite:
10
2021 - 2024
A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow- Univ.-Prof. Dr. med. JörgFaber,
- Dr. med. ArthurWingerter